EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Deciphering quinazoline derivatives’ interactions with EGFR: a computational quest for advanced cancer therapy through 3D-QSAR, virtual screening, and MD simulations

Sirajudheen Anwar, Jowaher Alanazi, Nafees Ahemad, Shafaq Raza, Tahir Ali Chohan, Hammad Saleem

Frontiers in Pharmacology · 24.10.2024 · 15

DOI: 10.3389/fphar.2024.1399372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 24.10.2024. Verfasst von Sirajudheen Anwar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The epidermal growth factor receptor (EGFR) presents a crucial target for combatting cancer mortality.

Methods

This study employs a suite of computational techniques, including 3D-QSAR, ligand-based virtual screening, molecular docking, fingerprinting analysis, ADME, and DFT-based analyses (MESP, HOMO, LUMO), supplemented by molecular dynamics simulations and MMGB/PBSA free energy calculations, to explore the binding dynamics of quinazoline derivatives with EGFR. With strong q2 and r2 values from CoMFA and CoMSIA models, our 3D- QSAR models reliably predict EGFR inhibitors’ efficacy. Results and Discussion Utilizing a potent model compound as a reference, an E-pharmacophore model was developed to sift through the eMolecules database, identifying 19 virtual screening hits based on ShapeTanimoto, ColourTanimoto, and TanimotoCombo scores. These hits, assessed via 3D- QSAR, showed pIC 50 predictions consistent with experimental data. Our analyses elucidate key features essential for EGFR inhibition, reinforced by ADME studies that reveal favorable pharmacokinetic profiles for most compounds. Among the primary phytochemicals examined, potential EGFR inhibitors were identified. Detailed MD simulation analyses on three select ligands—1Q1, 2Q17, and VS1—demonstrated their stability and consistent interaction over 200 ns, with MM/GBSA values corroborating their docking scores and highlighting 1Q1 and VS1’s superior EGFR1 affinity. These results position VS1 as an especially promising lead in EGFR1 inhibitor development, contributing valuable insights towards crafting novel, effective EGFR1 inhibitors.

Schlagwörter

Stichwörter der Autor:innen

3D-QSAREGFRanti-cancerfingerprintingin-silicosimulationsvirtual screening

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia.
  • School of Pharmacy, Monash University Malaysia, Petaling Jaya, Selangor, Malaysia.
  • Institute of Pharmaceutical Sciences (IPS), University of Veterinary and Animal Sciences (UVAS), Lahore, Pakistan.

Zitieren

APA

Anwar, S., Alanazi, J., Ahemad, N., Raza, S., Chohan, T. A., & Saleem, H. (2024). Deciphering quinazoline derivatives’ interactions with EGFR: a computational quest for advanced cancer therapy through 3D-QSAR, virtual screening, and MD simulations. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1399372

Vancouver

Anwar S, Alanazi J, Ahemad N, Raza S, Chohan TA, Saleem H. Deciphering quinazoline derivatives’ interactions with EGFR: a computational quest for advanced cancer therapy through 3D-QSAR, virtual screening, and MD simulations. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1399372

BibTeX
@article{Anwar2024,
  author = {Anwar, Sirajudheen and Alanazi, Jowaher and Ahemad, Nafees and Raza, Shafaq and Chohan, Tahir Ali and Saleem, Hammad},
  title = {Deciphering quinazoline derivatives’ interactions with EGFR: a computational quest for advanced cancer therapy through 3D-QSAR, virtual screening, and MD simulations},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1399372}
}
Kostenlos starten →